Levalbuterol

Treats or prevents bronchospasm with reversible obstructive airway disease. Xopenex HFA is labeled from age four; selected solution/concentrate labels begin at six. It is rescue bronchodilation, not a replacement for indicated anti-inflammatory asthma therapy. Poor response or increasing use requires reassessment rather than unlimited dose escalation.

Selected products are prescription inhalation formulations. HFA uses tartrate salt; nebulizer products use hydrochloride salt, with dose expressed as levalbuterol base. Reviewed old Oak/Akorn solution labels remain public selected records but do not prove current brand stock; verify the actually dispensed manufacturer/device and label. No oral, IV, continuous-nebulization or preterm-labor regimen is supplied.

Age four and older: two inhalations (90 mcg base) every 4–6 hours. Some patients obtain adequate effect from one inhalation (45 mcg) every four hours. Greater frequency/dose is not routinely recommended; loss of usual response needs prompt review of rescue and controller treatment.

Ages 6–11: 0.31 mg three times daily; routine dosing should not exceed 0.63 mg three times daily. Age twelve and older: start 0.63 mg three times daily, every 6–8 hours; 1.25 mg three times daily may benefit inadequate responders/severe asthma with close systemic-effect monitoring. Selected elderly solution instructions generally begin at 0.63 mg. These are product-label schedules, not an acute-care escalation algorithm.

Ready-to-use vials contain prescribed base dose in 3 mL and require no dilution. Concentrate contains 1.25 mg in 0.5 mL and must be diluted with sterile normal saline; selected IFU adds 2.5 mL to make 3 mL unless clinician directs otherwise. For doses below 1.25 mg, the concentrate label explicitly requires a non-concentrate formulation, not home splitting. Use prescribed jet-nebulizer/compressor and mask/mouthpiece; mixing with other nebulizer drugs and other systems is not established.

Shake before use. Prime with four sprays away from face before first use and after more than three unused days; the IFU also uses three consecutive days wording, so follow exact device instructions when the interval is uncertain. Inhale slowly/deeply while actuating; hold breath about ten seconds if possible, waiting about one minute before the next prescribed puff. Clean actuator weekly with warm water and air-dry fully; keep metal canister dry and use only its matched actuator.

Renal impairment can increase toxicity concern; select cautiously and reassess with monitoring, especially at high exposure. Hepatic PK effects are unstudied. No numerical eGFR/CrCl reduction or dialysis supplemental dose is established, and no guaranteed racemic-albuterol equivalence or universal maximum across devices is supplied.

Known hypersensitivity to levalbuterol/racemic albuterol contraindicates the selected products; HFA also explicitly includes its other ingredients. Reactions can include hives, angioedema, bronchospasm and anaphylaxis. Review the actual formulation and prior reaction; do not substitute another albuterol product without assessment.

No boxed warning appears in the selected inhaled labels. Life-threatening bronchospasm/allergy, severe exacerbation and excess-use warnings still apply. These inhaled products are not approved for treating preterm labor.

Possible effects include tremor, nervousness, headache, tachycardia/palpitations, throat irritation and nausea. Trials also report respiratory symptoms/infections and pediatric vomiting; trial events are not all proven caused by treatment. Serious postmarketing reports include arrhythmia, chest pain, metabolic acidosis, allergy and worsening breathing, with uncertain frequencies.

Avoid unsupervised concomitant short-acting sympathomimetic bronchodilators/epinephrine; additional adrenergic treatment requires caution for cardiovascular effects. Beta-blockers can oppose bronchodilation and provoke severe bronchospasm. If a compelling cardiac indication requires one, clinicians may consider a cardioselective agent with caution; do not abruptly stop essential cardiac therapy.

Loop/thiazide diuretics can add low-potassium/ECG effects; consider potassium checks. Digoxin concentration effects are based largely on racemic-albuterol studies and warrant assessment rather than an assumed fixed levalbuterol correction. Use extreme caution with MAO inhibitors or tricyclic antidepressants during treatment or within two weeks after stopping because vascular effects may be amplified.

Physical/chemical compatibility, safety and efficacy when mixed with other nebulizer drugs are not established in selected labels. Use verified sterile saline dilution only where required; an inhaler puffer is not a source of nebulizer liquid.

HFA is labeled ≥ four; below four it is not indicated and trials failed the primary endpoint with more asthma-related events. Solution/concentrate are labeled ≥ six; younger trials likewise do not establish benefit. Older patients need cautious selection and clinical monitoring; selected solution generally starts 0.63 mg. No infant/neonatal algorithm is provided.

Renal excretion of drug/metabolite is substantial and renal disease can reduce clearance; monitor response and toxicity rather than use an invented fixed dose reduction. Hepatic PK effects are not evaluated. Cardiovascular/metabolic disease may add concern even when inhaled delivery is used.

Adequate controlled human pregnancy data are lacking. Poor asthma control itself increases maternal/fetal risk; maintain an assessed treatment plan rather than stop rescue therapy independently. During labor, use for bronchospasm only when benefit outweighs uterine-contractility risk. It is not approved tocolysis; serious maternal effects have been reported with beta 2 agonists in that context.

Human milk transfer, infant effects and milk-production effects are unknown. Weigh maternal need and feeding benefits with clinical assessment; do not claim zero exposure or an automatic requirement to cease breastfeeding from these labels.

Beta 2 receptor activation raises cyclic AMP and promotes bronchial smooth-muscle relaxation. Cardiac beta receptors and systemic adrenergic effects explain remaining tachycardia/BP risks. This is short-acting bronchodilation, not direct replacement of airway anti-inflammatory control.

Sulfotransferase metabolism and renal excretion contribute to disposition. Nebulizer adult single-dose studies report plasma half-life around 3.3 hours, with variable exposure; HFA population modeling differs. Pediatric exposure can differ from adults, supporting product-specific doses. Study comparisons with racemic albuterol do not establish universally fewer side effects or automatic conversion.

Assess symptom relief, exacerbation frequency, rescue-use trend, technique/adherence and anti-inflammatory treatment. Check pulse/BP and relevant cardiac/electrolyte/glucose/renal risks when indicated; no routine universal laboratory schedule is supplied. A sudden rise in use or reduced response requires prompt reassessment, not a self-directed dose increase.

Know the action plan and seek urgent care for severe/worsening dyspnea, immediate post-dose wheeze, chest pain, serious palpitations or allergy. Keep rescue supply available and do not substitute the rescue product for prescribed controller treatment. Verify base dose, vial volume and dilution; clean equipment and use exact label/storage instructions.

Selected Xopenex HFA 15 g canister NDC 27437-056-01 provides 200 actuations, blue actuator/red cap and dose indicator. Selected legacy Xopenex 0.63 mg/3 mL carton NDC 17478-173-24; concentrate 1.25 mg/0.5 mL NDC 17478-171-30. These latter label examples do not certify current Oak/Akorn supply; confirm actual dispensing product.

HFA delivers 45 mcg levalbuterol base from mouthpiece after priming (59 mcg tartrate). Ready-to-use preservative-free vials supply 0.31, 0.63 or 1.25 mg base in 3 mL. Concentrate supplies 1.25 mg base in 0.5 mL and requires dilution. Do not confuse vial dose with concentration or copy HFA salt mass into nebulizer dosing.

HFA: 20–25°C, mouthpiece down, protect from freezing/sunlight/heat; do not puncture/incinerate and avoid temperatures > 120°F. Refill near red indicator and discard at zero/200 actuations. Selected 3 mL solution: 20–25°C protected foil; use within two weeks after pouch opening, or within one week if removed but protected from light. Concentrate: 20–25°C protected foil; open just before administration and use immediately after pouch opening. Discard discolored solution and single-use leftovers. Other generics need their own limits.